PCOS Renamed PMOS: Discover How the New Diagnosis Could Transform Care for 170 Million Women

LEADING CHANGE IN WOMEN’S HEALTH After 14 years of international research and consultation with more than 22,000 patients, clinicians and scientists, polycystic ovary syndrome (PCOS) has officially been renamed polyendocrine metabolic ovarian syndrome (PMOS). The consensus statement, published this week in The Lancet, aims to correct decades of confusion by removing the misleading reference to “cysts” and highlighting the condition’s hormonal and metabolic roots. WHY THE NAME MATTERS • Broader scope: Many people diagnosed with PCOS never develop ovarian cysts; the new term stresses endocrine and metabolic dysfunction that can affect the entire body, from insulin resistance to cardiovascular health. • Earlier diagnosis: Experts hope a clearer label will prompt primary-care doctors—not just gynecologists—to screen for symptoms such as irregular periods, acne, weight gain and pre-diabetes. • Reduced stigma: Dropping the focus on “cysts” may lessen anxiety for newly diagnosed patients who assume surgery is inevitable. KEY SYMPTOMS AND RISKS PMOS affects an estimated one in eight women of reproductive age worldwide and is a leading cause of anovulatory infertility. Beyond fertility, the syndrome raises lifelong risks of type 2 diabetes, high cholesterol, fatty-liver disease, depression and endometrial cancer. WHAT CHANGES FOR PATIENTS? • Diagnostic criteria—high androgen levels, ovulatory dysfunction and ovarian morphology—remain the same. • Lifestyle therapy (nutrition, exercise, weight management) is still first-line treatment, often paired with metformin or combined oral contraceptives for hormonal balance. • Insurance codes and educational materials will gradually adopt “PMOS”; patients are encouraged to use both terms during the transition. EXPERT VOICES “Renaming PCOS to PMOS recognizes that this is a systemic endocrine-metabolic disorder, not simply an ovary problem,” said Professor Helena Teede, who led the Monash-coordinated taskforce. Reproductive endocrinologist Dr Natalie Crawford added that the update could “unlock new research funding streams that were previously funneled only into gynecology.” WHAT’S NEXT Global medical societies are expected to release updated clinical guidelines under the PMOS banner within the year. In the meantime, doctors advise patients currently labeled with PCOS to keep all appointments and medications unchanged; only the name is different. BOTTOM LINE The shift from PCOS to PMOS marks a pivotal moment in women’s health, promising clearer communication, earlier detection and a renewed push for comprehensive, whole-body care.